Power Law company profile

Immunome

Biotech & Life Sciences · Bothell, United States · Founded 2008 · IPO 2020 Unicorn

Immunome - Novel Immunotherapies for Cancer

Valuation

$1.95B

Market cap · May/2026

Revenue

$6.9M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

9 investors on Immunome's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage

Robin Hood Ventures

Evolution Corporate Advisors

BioAdvance

Series B+ 6 investors entered at this stage

Enavate Sciences

Avidity Partners

Woodline Partners

Janus Henderson Investors

Redmile Group

EcoR1 Capital

Global footprint

Where Immunome has talent and traffic

Workforce by country

🇺🇸 United States · Bothell HQ

Book a demo for the full country breakdown

Web traffic by country

8.6K monthly visits
across markets

🇺🇸 United States70.9%

🇬🇧 United Kingdom14%

🇨🇦 Canada12.8%

🇯🇵 Japan2.3%

Top 4 markets shown

Market sentiment

What the market is saying about Immunome

An AI-synthesized read of the highest-engagement posts about Immunome on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Immunome on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles